DiaMedica Therapeutics Inc.
DMAC · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $19 | $13 | $8 | $9 |
| G&A Expenses | $7 | $8 | $6 | $5 |
| SG&A Expenses | $8 | $8 | $6 | $5 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $27 | $21 | $14 | $14 |
| Operating Income | -$27 | -$21 | -$14 | -$14 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $2 | $2 | $0 | $0 |
| Pre-Tax Income | -$24 | -$19 | -$14 | -$14 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$24 | -$19 | -$14 | -$14 |
| % Margin | – | – | – | – |
| EPS | -0.6 | -0.6 | -0.52 | -0.65 |
| % Growth | 0% | -15.4% | 20% | – |
| EPS Diluted | -0.6 | -0.6 | -0.52 | -0.65 |
| Weighted Avg Shares Out | 40 | 33 | 26 | 21 |
| Weighted Avg Shares Out Dil | 40 | 33 | 26 | 21 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$27 | -$21 | -$14 | -$14 |
| % Margin | – | – | – | – |